VX01 targets the fungal invasion,CotH3 and is proven in preclinical testing to treat mucormycosis alone or synergistically with FDA-approved antifungal agents.

The award was issued by NIAID Preclinical service (PCS) to select a Research Cell Bank to further the establishment of a Master Cell Bank. Vitalex also recently received a competitive score of 24 on a Phase II SBIR grant.

Dr Dr. Ashraf S Ibrahim's Lab from Harbor-UCLA Infectious Diseases presenting potential novel #antifungals vs #mucor @IDWeek2022

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections Dr. Ashraf S Ibrahim's Lab Ana Alastruey Nkechi mdpi.com/1904744

Vitalex Biosciences, a spinoff start-up company of The Lundquist Institute for Biomedical Innovation, is proud to announce today that its VX-01 monoclonal antibody program targeting the debilitating indication of mucormycosis has been awarded an SBIR Phase 2 grant from NIAID/NIH.

Great seminar about #aspergillus by Gustavo Goldman, from São Paulo Fungal Group at The Lundquist Institute

Congrats Kieren Marr David Andes Nathan Wiederhold Tom Patterson Dr. Ashraf S Ibrahim's Lab Bill Steinbach etc on this achievement!

The Lundquist Institute Investigator Ashraf Ibrahim, PhD, has been selected by the Medical Mycology Society of the Americas (MMSA) to receive the 2024 Billy H. Cooper Award for his continuous outstanding achievement in clinical mycology. TLI congratulates Dr Ibrahim for this high honor.

That’s a wrap! After 3 weeks in L.A I just have thankful words for the fantastic and welcoming Dr. Ashraf S Ibrahim's Lab. Loads of learning at The Lundquist Institute see you later California @[email protected] MRC Centre for Medical Mycology #Collaboration #STEM #FungiFriday

🔬✨ National Immunization Awareness Month✨🔬 This August, we spotlight the critical role of vaccines and immunotherapies in our fight against infectious diseases. Learn more about Dr. Ashraf S Ibrahim's Lab's work and The Lundquist Institute below: instagram.com/p/C-6AZhTyhd8/…

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response | Science Translational Medicine science.org/doi/10.1126/sc…

Happy to see our paper describing the activity and MoA of a humanized MAb (VX-01) against mucormycosis published in Sciences Translational Medicine. This takes us a step closer to clinical testing on the road to provide better care for this lethal fungal infection.

Mucormycosis is a fungal infection that causes severe disease and fatality, especially in immunocompromised individuals. While vaccines and immunotherapeutics have been available in combating viral and bacterial infections, approved antifungal immunotherapies are lacking. Thanks

Mucormycosis is a fungal infection that causes severe disease and fatality. “Mucormycosis usually occurs in patients who suffer from weakened immune system, such as patients with poorly controlled diabetes, cancer patients undergoing chemotherapy, and transplant patients,” says

IT'S A TWO-FER! A huge congratulations to TLI Investigator Dr. Ashraf S Ibrahim's Lab for receiving the 43rd Kuwait Prize by the KFAS. This prestigious award honors Kuwaiti and Arab scientists for their exceptional scientific and intellectual contributions on a global scale.🚀 Dr.

Honored to welcome U.S. Senator Bill Cassidy, M.D. to The Lundquist Institute. I showed him Dr. Ashraf S Ibrahim's Lab, where we study host–pathogen interactions, develop immunotherapies for mucormycosis, and advance vaccines against drug-resistant infections. Grateful for his support of biomedical research.

The Lundquist Institute, together with its start-up company Vitalex Bioscience, is proud to announce a significant advancement in fungal vaccine research.🔬 Supported by a highly competitive $40 million contract from the NIH’s NIAID News, the team is moving its second-generation,